Highlights of progress achieved by PneumoADIP and partners during 2005.

Highlights of progress achieved by PneumoADIP and partners during 2005

Progress & Next Steps

The following report documents progress made by PneumoADIP during 2005. It outlines ways in which the international community is working together to accelerate access to life-saving vaccine against a serious common disease for children in the developing world. We hope you will find the report to be both informative and inspiring. The task in front of us is still enormous, and it is essential that everyone involved continues to work together towards our collective goal.
Download the full report [PDF; 2.61MB]

Establishing Value: Research

1. In collaboration with the WHO:

  • Established rigorous, systematic methods for estimating the global, regional, and local burden of pneumococcal disease.
  • Implemented standard methods for conducting pneumonia and meningitis surveillance by supporting networks of investigators throughout the world.

2. Selected 8 field sites in Asia for further development as sites that can evaluate the public health impact of pneumococcal vaccines in the region.

3. Awarded 20 Small Grants to support local investigators in 17 developing countries establish and communicate the burden of pneumococcal disease and the value of vaccination.

Communicating Value: Communications

1. Documented a 7-fold increase in media coverage of pneumococcal disease and vaccine issues, driven in large part by PneumoADIP's media outreach efforts.

2. Broadcasted to over 250 million households in January 2005, the BBC World documentary "Kill or Cure?" focused on the human face of pneumococcal disease.

3. Assured widespread coverage of the results of The Gambian pneumococcal vaccine trial.

Delivering Value: Vaccine & Supply

1. Developed a credible strategic demand forecast for pneumococcal vaccine introduction in the 72 GAVI-eligible countries.

2. Provided a convincing case to Group of 7 (G7) finance ministry representatives that the G7 should pilot the innovative financing mechanism called Advance Market Commitment by investing $1.5 billion or more to procure pneumococcal vaccines for developing countries over the next 15 years.

3. Built a comprehensive forecast of pneumococcal vaccine supply from 2006-2025 that includes projections of the roles for both multi-national and emerging market suppliers, and conjugate and common protein vaccines.